Quanterix Corp

QTRX

Explore Our Financial Data > Companies > Quanterix Corp

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	QTRX
CIK	0001503274
SIC	3826
Sector	Manufacturing
Industry Category	Measuring And Control Equipment
Industry Group	Lab Analytical Instruments

Contact

Address	900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821
Website	quanterix.com
Phone	617-301-9400
CEO	Masoud Toloue
Employees	460

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$135.69 million
Pre-Tax Income	$-50.53 million
Net Income	$-47.87 million
Net Income to Common	$-47.87 million
EPS	$-1.24

View All

Balance Sheet

Cash	$76.51 million
Assets	$396.51 million
Liabilities	$80.12 million
Common Equity	$316.39 million
Liabilities & Equity	$396.51 million

View All

Cash Flow Statement

Net Income	$-47.87 million
Cash From Operating Activities	$-28.89 million
Cash From Investing Activities	$59.69 million
Cash From Financing Activities	$-50,000.00
Change in Cash	$30.75 million

View All

Calculations

NOPAT	$-44.68 million
EBITDA	$-61.56 million
Price to Earnings	N/A
Price to Book	$0.68
ROE	-14.51%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass., July 11, 2025--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ("RSUs") representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq

Article Link

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

BILLERICA, Mass., July 08, 2025--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets.

Article Link

Quanterix Expands Reach with IVD and Large Reference Labs

BILLERICA, Mass., June 23, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems.

Article Link

Insider Spends US$1.1m Buying More Shares In Quanterix

Quanterix Corporation ( NASDAQ:QTRX ) shareholders (or potential shareholders) will be happy to see that the...

Article Link

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time.

Article Link